Abstract

The accurate diagnosis and follow-up of neuroendocrine and neuroectodermal tumors at the time of diagnosis are crucial in managing the treatment process for patients. Neuroendocrine tumors (NETs) are rare and heterogeneous tumors that arise from neuroendocrine cells. They are most commonly found in the digestive system and lungs and can present diverse clinical symptoms due to their hormone-secreting potential. On the other hand, neuroectodermal tumors originate from neural crest-derived cells and can manifest in various clinical conditions. Primitive neuroectodermal tumors, such as neuroblastoma and medulloblastoma, are part of this group. Hybrid imaging techniques, such as positron emission tomography/magnetic resonance, offer significant advantages in staging, restaging, assessing treatment response, and determining metabolic activity and receptor expression of these tumors. These techniques combine both functional and anatomical data, enabling more accurate evaluations and treatment planning.